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Abstract
Background: Global coronary heart disease (CHD) risk assessment is recommended to guide primary preventive
pharmacotherapy. However, little is known about physicians’ understanding and use of global CHD risk assessment.
Our objective was to examine US physicians’ awareness, use, and attitudes regarding global CHD risk assessment in
clinical practice, and how these vary by provider specialty.
Methods: Using a web-based survey of US family physicians, general internists, and cardiologists, we examined
awareness of tools available to calculate CHD risk, method and use of CHD risk assessment, attitudes towards CHD
risk assessment, and frequency of using CHD risk assessment to guide recommendations of aspirin, lipid-lowering
and blood pressure (BP) lowering therapies for primary prevention. Characteristics of physicians indicating they use
CHD risk assessments were compared in unadjusted and adjusted analyses.
Results: A total of 952 physicians completed the questionnaire, with 92% reporting awareness of tools available to
calculate CHD global risk. Among those aware of such tools, over 80% agreed that CHD risk calculation is useful,
improves patient care, and leads to better decisions about recommending preventive therapies. However, only
41% use CHD risk assessment in practice. The most commonly reported barrier to CHD risk assessment is that it is
too time consuming. Among respondents who calculate global CHD risk, 69% indicated they use it to guide lipid
lowering therapy recommendations; 54% use it to guide aspirin therapy recommendations; and 48% use it to
guide BP lowering therapy. Only 40% of respondents who use global CHD risk routinely tell patients their risk. Use
of a personal digital assistant or smart phone was associated with reported use of CHD risk assessment (adjusted
OR 1.58; 95% CI 1.17-2.12).
Conclusions: Reported awareness of tools to calculate global CHD risk appears high, but the majority of physicians
in this sample do not use CHD risk assessments in practice. A minority of physicians in this sample use global CHD
risk to guide prescription decisions or to motivate patients. Educational interventions and system improvements to
improve physicians’ effective use of global CHD risk assessment should be developed and tested.
Background
Coronary heart disease (CHD) is the major killer of
American men and women, responsible for one out of
every six deaths in the United States (US) [1]. Remark-
ably, CHD is also largely preventable. According to a
study of 52 countries, nine easily measured and poten-
tially modifiable risk factors account for over 90% of the
risk of an initial acute myocardial infarction [2]. Primary
prevention of CHD should be a top priority due to the
high rate of first events that are fatal, disabling, or that
require expensive management [3]. Unfortunately, the
majority of individuals with elevated CHD risk factors
are not using appropriate risk reducing therapies [4-7].
One contributing factor is that clinicians often do not
accurately estimate a patient’s risk for CHD [8-12].
The risk for the development of CHD varies greatly
among individuals. Effective clinical primary prevention
of CHD therefore requires individualized interventions
that range in intensity. In order to appropriately select
medical interventions for primary prevention it is
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necessary to stratify patients based on an assessment of
cardiovascular risk [13]. Current guidelines suggest that
all patients ≥ 40 years of age or those with ≥ 2 risk fac-
tors should have their 10-year risk of CHD assessed
every 5 years or as risk factors change, with a global risk
assessment [3]. The risk factors used to calculate global
CHD risk include: age, sex, smoking status, blood pres-
sure (BP), total cholesterol (sometimes low density lipo-
protein (LDL)), high density lipoprotein (HDL)
cholesterol, and in some risk tools, diabetes [3]. There
are many user-friendly, easily accessible tools available
for estimating a patient’s CHD risk including risk charts
and risk calculators for personal digital assistants, perso-
nal computers, and web-based use [14]. When com-
pared to the full Framingham equations for identifying
patients at increased risk, these tools are generally accu-
rate, although Framingham-based estimates may not
apply equally to all ethnic groups [3,14].
Calculation of a patient’s risk for CHD has many advan-
tages in clinical practice. It allows improved prediction of
incident events, enabling physicians to better identify
patients who warrant preventive medications [15]. Use of
global risk may also improve intermediate and long-term
outcomes for patients, particularly when combined with
counseling [15,16]. Patients may gain an improved under-
standing of their risk and the reason for any proposed
interventions, which may increase motivation to adhere to
any preventive medications that are prescribed [15,16].
While advantages of using global risk assessment in
the primary prevention of CHD have been documented,
little is known about the actual use of global CHD risk
in clinical practice. The purpose of this study was to
examine US physicians’ awareness, attitudes towards
CHD risk assessment, and use of CHD risk assessment
when considering clinical interventions for primary pre-
vention, and whether these vary across three relevant
clinical specialties.
Methods
Overall design
This study was a cross-sectional, web-based survey of a
national sample of family physicians, general internists,
and cardiologists. The survey was designed by the inves-
tigators, pretested among a convenience sample of
family physicians, general internists, and cardiologists,
and automated by survey experts at the Odum Institute
for Research in Social Science affiliated with the Univer-
sity of North Carolina at Chapel Hill. This study was
approved by the Office of Human Research Ethics at the
University of North Carolina at Chapel Hill.
Study sample and invitations to participate
The sampling frame was family physicians who are
members of the American Academy of Family
Physicians (AAFP) and general internists and cardiolo-
gists who are members of the American College of Phy-
sicians (ACP). A mailing list of 9000 members randomly
selected from a database of members of the AAFP
(family physicians) and the ACP (general internists and
cardiologists) was obtained. The list consisted of 2623
family physicians (377 members were excluded because
they were medical students), 3000 general internists, and
3000 cardiologists.
Personalized letters of invitation were mailed to the
8623 physicians. These letters described the study and
provided a URL for the online survey with an individua-
lized identification code to allow tracking of non-
responders. At two and four weeks after the initial invi-
tation was sent out, non-respondents were mailed
reminder letters. As an incentive to participate, physi-
cians who wished to do so could have their name
entered into a drawing for one of two $500 gift cards.
Variables
Data obtained from the survey included physicians’
awareness of tools available to calculate CHD risk, fre-
quency of using global CHD risk in clinical practice,
method of CHD risk assessment, and how often CHD
risk calculations are used to guide prescription of
aspirin, lipid-lowering, and BP lowering therapies for
primary prevention (Appendix). We collected data on
attitudes regarding the usefulness of CHD risk calcula-
tions and, among those who reported not using global
CHD risk, reasons for not doing so. Information regard-
ing respondents’ specialty type, sex, year of graduation
from medical school, amount of patient care time, type
of practice setting, region of the country, use of electro-
nic medical records and computers in exam rooms, and
use of a personal digital assistant (PDA) or smart phone
during patient encounters was also collected.
Analysis
Responses to each item were tabulated, missing
responses were excluded, and differences were com-
pared by respondent characteristics. Testing for signifi-
cant differences was performed using analysis of
variance (ANOVA) for Likert-scaled outcomes, chi-
square for categorical outcomes, and Kruskal-Wallis for
ordinal outcomes. Attitudes towards CHD risk assess-
ment were examined among physicians who reported
being aware of CHD risk assessment using five state-
ments. Physicians responding, “Strongly Agree”, or
Agree” were combined into an “Agree” category, while
subjects who responded, “Disagree” or “Strongly Dis-
agree” were combined into a “Disagree” category. (There
was no “Neutral” category.) Proportions agreeing with
each statement were tabulated and compared between
specialty groups. Physicians who indicated that they
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were aware of and, “occasionally”, “most of the time”, or
“always” obtain a calculation of a patients global CHD
risk for primary prevention (based on the question,
“When considering primary prevention of coronary
heart disease in adults, how often do you obtain a calcu-
lation of a patient’s global (overall) coronary heart dis-
ease risk?”) were combined into a “CHD user” category.
Those who indicated they were aware of but “never” or
“rarely” calculated a patient’s global CHD risk for pri-
mary prevention based on this question were combined
into a “non-CHD user” category. Characteristics of the
respondents in each category were compared in unad-
justed analyses and then by logistic regression initially
adjusting for specialty, years in practice, amount of
patient care time, office practice setting, use of EMR,
use of internet in patient exam rooms, sex, region of the
country, and PDA use. Variables with an associated p-
value > 0.10 were then excluded from a final model.
Among the “non-CHD user” group, potential reasons
for not calculating patient’s global CHD risk for primary
prevention were examined through responses to six
statements that were rated for importance on a Likert-
scale from 0-5 (with 0 being not important at all- 5
being extremely important). The ratings were averaged
for each statement and compared in unadjusted analyses
by specialty.
To examine physicians’ use of CHD risk to guide pri-
mary preventive pharmacological therapy, respondents
indicating that they are aware of and use CHD risk esti-
mates to guide recommendations, “occasionally”, “most
of the time”, or “always or nearly always”, were categor-
ized as those who use CHD risk to guide preventive
therapy and were compared to those who rarely or
never use such calculations. Results were also compared
by specialty.
Statistically significant differences were defined as a p-
value < 0.05. To assess the potential for nonresponse
bias, geographic regions between respondents and non-
respondents were compared. All analyses were per-
formed using Stata 10.1 statistical software (StataCorp,
College Station, TX).
Results
Study participants
Of the 8623 letters mailed, 74 were returned as undeli-
verable, including 8 because the intended recipient was
deceased, and 3 because of delivery refusal. A total of
1238 physicians participated in the survey. Respondents
who indicated they did not see patients in the office set-
ting (n = 251) or whose practicing specialty was one
other than family medicine, general internal medicine,
or cardiology (n = 55) were excluded. The adjusted
response rate was 15%. The final sample consisted of
952 physicians: 390 (41%) family physicians, 272 (29%)
general internists, and 290 (30%) cardiologists (Table 1).
A total of 932 (98%) of respondents completed every
survey item, while 20 (2%) submitted partial responses.
Nonrespondents were compared to respondents by geo-
graphic region, and the two groups were very similar
(Additional File 1).
Of those who responded, the majority were male
(74%), spent more than 75% of work time in office
based patient care (56%), use EMR in their practices
(59%), have computers in patient exam rooms (56%),
and have been in practice for 10 years or more (79%).
Small group practices were the most common practice
setting (32%), and the most common region of the
country practiced in was the South (33%).
Across provider respondent groups, there were some
notable differences. Cardiologists (94%) who responded
were more likely than general internists (75%) and
family physicians (58%) to be male. Cardiologists (88%)
were more likely than general internists (70%) or family
physicians (40%) to have been in practice for more than
20 years. General internists and family physicians spent
more time in office-based care than cardiologists. Family
physicians (62%) were more likely than general internists
(37%) and cardiologists (38%) to use a PDA or smart-
phone when seeing patients in the office.
Awareness and use of tools to calculate global CHD risk
Of all physicians (N = 951) who responded to the ques-
tion, “Have you heard about tools to calculate a patients
overall risk of coronary heart disease in the next 10
years (global CHD risk)?” 873 responded “yes” (92%).
When those in this group were asked, “When consider-
ing primary prevention of CHD in adults, how often do
you obtain a calculation of a patient’s global (overall)
coronary heart disease risk?”, a total of 358 respondents
(41%) reported using global CHD risk at least occasion-
ally when considering primary prevention of CHD in
adults, including 67 (8%) who reported always or nearly
always doing so. The remaining 505 physicians (59%)
who responded to this question (10 responses were
missing) reported that they “rarely” or “never” use global
CHD risk assessment when considering primary preven-
tion of CHD in adults. One third of respondents (33%)
who use global CHD risk in practice reported using a
web-based application, while 27% use a paper chart and
26% use a program on a PDA or smartphone to obtain
their patient’s risk estimate (Table 2). Few (14%) use
other methods such as non-web based computer pro-
grams (e.g., a spreadsheet) or calculators embedded in
EMRs.
The majority of respondents who indicated they were
aware of CHD risk assessment tools (with no signifi-
cant difference between specialties) agreed or strongly
agreed that global CHD risk calculation is useful,
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improves patient care, leads to better decisions about
whether or not to recommend therapies to prevent
heart disease events, and increases the likelihood that
they will recommend risk reducing therapies to
prevent heart disease (Table 3). However, a minority
who indicated they were aware of CHD risk assess-
ment tools reported actually using global CHD risk to
guide their primary preventive pharmacotherapy
recommendations.
Approximately 69% of respondents who calculate glo-
bal CHD risk use it to guide lipid lowering therapy
recommendations; 54% use it to guide aspirin therapy
recommendations; and 48% use it to guide BP lowering
therapy recommendations (Table 4). Approximately 40%
of respondents who use CHD risk calculation reported
that they tell their patients his/her CHD risk estimation
“most of the time”, “nearly always”, or “always”. Cardiol-
ogists were more likely to report that they tell a patient
Table 1 Characteristics of respondents (N = 952)
All Family physicians
(n = 390)
General Internists
(n = 272)
Cardiologists
(n = 290)
P- value*
% % % %
% Male 73.6 57.8 74.6 94.3 < 0.001
Years in Practice < 0.001
> 20 63.1 40.2 70.2 88.0
10-19 18.8 26.0 19.9 8.0
< 10 18.1 33.9 9.9 4.0
Region of country 0.003
Northeast 23.7 18.3 25.7 29.3
South 33.2 34.3 33.6 31.4
Midwest 24.2 24.5 24.2 23.9
West 18.9 22.9 16.6 15.4
Time spent in office based care < 0.001
> 75% 56.5 71.0 63.5 30.3
51-74% 14.7 9.5 11.1 25.1
50% 8.5 5.6 6.6 14.3
25-49% 10.2 9.0 6.6 15.3
< 25% 10.0 4.9 12.2 15.0
Practice setting < 0.001
Solo Practice 12.5 9.7 14.8 14.1
Small Group (2-9 clinicians) 32.0 36.7 32.6 25.2
Large Single Specialty group (10+ clinicians) 11.8 9.7 4.8 21.0
Large multi-specialty group (10+ clinicians) 13.9 13.9 18.5 9.7
Academic group 20.6 21.8 17.0 22.4
Other 9.2 8.2 12.2 7.6
Use of electronic medical records 59.2 59.4 58.2 59.9 0.91
Computers in exam rooms 55.5 56.8 54.1 55.2 0.78
Internet connection for computers in exam rooms 94.1 92.7 95.9 94.3 0.46
Use personal digital assistant or smartphone 47.4 61.5 36.9 38.1 < 0.001
*Overall P-values based on Pearson’s Chi square test of significance or Kruskal-Wallis test between specialty groups
Table 2 Reported method of CHD global risk assessment among physicians who use CHD risk assessment (N = 358)
All, % Family physicians, % General internists, % Cardiologists, % P- Value*
Paper chart (n = 96) 27.0 22.8 25.7 32.3 0.18
Web-based (n = 117) 32.9 29.5 40.5 32.3 0.12
Non-web-based computer program (n = 23) 6.2 3.4 8.1 8.3 0.01
Program on a personal digital assistant (n = 94) 26.1 34.9 18.9 20.3 0.02
Other (n = 28) 7.9 9.4 6.8 6.8 0.09
* Overall P-value based on Pearson’s Chi square test for significance between specialty groups
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his/her CHD risk estimation (49%) than were family
physicians and general internists (38% and 33% respec-
tively) (p < 0.01).
Physicians who use global CHD risk assessment
Among physicians who reported being aware of global
CHD risk assessment tools, reports of using global CHD
risk assessment differed by specialty, years in practice,
time spent in office-based care, and use of a PDA or
smartphone (Table 5). Among cardiologists, 49%
reported using global CHD risk assessment, compared
to approximately 42% of family physicians and 32% of
general internists (p < 0.001). Those who had been in
practice for 10-19 years (50%) were more likely than
those who have been in practice for less than 10 (41%)
and more than 20 years (39%) to use CHD risk assess-
ment (p = 0.02). Respondents who indicated they used a
PDA or smartphone when seeing patients were more
likely to report using global CHD risk assessment (47%
vs. 36%, p = 0.001). There were no differences in use of
global CHD risk assessment among those who used
EMRs or those who had computers/internet connection
in exam rooms. The final multivariate logistic regression
model showed that after adjusting for specialty, years in
practice, office-based care time, and PDA or smart
phone use, physicians who reported using a PDA or
smartphone had greater odds of using CHD risk assess-
ment in practice (OR 1.58; 95% CI 1.17-2.12) (Table 6).
Cardiologists, physicians in practice 10-19 years, and
those spending either 50% time or 51-74% time in office
based care also had greater odds of being users.
Reasons for not using global CHD risk assessment
Among physicians’ who reported not using CHD risk
assessment (N = 492; 505 minus 13 missing responses),
the reason with the highest mean importance rating (2.6
± 1.6) on a 0 to 5 scale was, “It is too time consuming”
(Table 7). Family physicians (2.8) rated this reason
higher than general internists (2.6) and cardiologists
(2.3) (p = .02). The reason with the next highest mean
importance rating was, “I do not find it useful in prac-
tice” (2.2 ± 1.6). Cardiologists (2.9) rated this reason
Table 3 Percentage of respondents aware of CHD risk assessment tools who agree with the given statements
regarding global CHD risk assessment (N = 873)
All Family
Physicians
General
Internists
Cardiologists P-
value*
% % % %
I find global CHD risk calculation useful (n = 834) 83.8 85.6 80.9 84.0 0.33
Global CHD risk calculation wastes time (n = 811) 18.7 17.1 18.3 21.4 0.40
Global CHD risk calculation improves patient care (n = 825) 80.9 82.8 80.6 78.5 0.41
Global CHD risk calculation leads to better decisions about whether or not to recommend
therapies to prevent heart disease events (n = 819)
81.1 82.8 82.8 77.3 0.19
Global CHD risk calculation increases the likelihood that I will recommend risk-reducing
therapies to prevent heart disease
(n = 809)
71.2 73.5 73.7 65.9 0.08
CHD = coronary heart disease
*Overall p-values based on Pearson’s chi squared test for significance between specialty groups
Table 4 Physicians’ reports of how they use CHD global risk assessment for primary prevention, among those who use
CHD risk assessment (N = 358)
All Family
Physicians
General
Internists
Cardiologists P-
value*
% % % %
Use global CHD risk estimate to guide lipid lowering therapy recommendations (n
= 355)
69.0 63.5 72.4 73.3 0.16
Use global CHD risk estimate to guide aspirin therapy recommendations (n = 350) 53.7 52.4 51.4 56.5 0.72
Use global CHD risk estimate to guide blood pressure lowering therapy
recommendations (n = 356)
48.3 48.7 44.7 50.0 0.76
Use global CHD risk estimate to guide any primary prevention therapy
recommendation (n = 358) †
76.8 73.2 79.0 79.7 0.38
Tell patients their global CHD risk (n = 352) 40.1 37.7 33.0 49.2 0.01
CHD = coronary heart disease
*Overall p-values based on Pearson’s chi squared test for significance between specialty groups
† Based on using risk estimate to guide lipid lowering, aspirin, or blood pressure lowering recommendation
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higher than general internists (2.0) and family physicians
(1.9) (p < .0001). Lack of familiarity with how to use the
risk calculation and lack of easy-to-use tools were rated
slightly less important, particularly by the family physi-
cian and general internist respondents. Lack of accurate
tools and a perception that the risk calculation is not
valid for [my] patients received ratings indicating they
were the least important of the listed reasons.
Discussion
We sought to examine physicians’ self-reported aware-
ness, use in clinical practice, and attitudes regarding
CHD global risk assessment for primary prevention and
how this varies by provider type. Our study found that
among a sample of US physicians: (1) awareness of tools
to calculate CHD global risk is extremely high, (2) use
of CHD global risk calculation in practice is low, (3) the
most strongly endorsed reason for not calculating a
patient’s global CHD risk appears to be that it is too
time consuming, (4) overall use of global CHD risk cal-
culation to guide primary preventive pharmacologic
therapy is low and infrequently used to guide aspirin
recommendations.
Our finding that use of CHD global risk calculation by
US physicians is low is concerning since national guide-
lines for primary prevention of CHD are based on
Table 5 Proportion of physicians who are aware of and
report using CHD risk assessment, by subgroups of
physician characteristics (N = 873)
% P-
value*
All 41.4
Specialty < 0.001†
Family medicine 41.7
Internal medicine 31.9
Cardiology 49.4
Years in practice 0.02
> 20 38.9
10-19 49.7
< 10 41.3
Sex 0.92
Male 41.6
Female 41.2
Region of country 0.48
Northeast 44.0
Southeast 42.0
Midwest 37.0
West/West coast 43.1
Time spent in Office based patient care 0.002‡
> 75% 36.3
51-74% 50.8
50% 57.5
25-49% 43.7
< 25% 40
Office Setting 0.37
Solo practice 39.4
Small group 42.1
Large Single Specialty 44.2
Large Multi-specialty 33.1
Academic Group 45.9
Other 41.1
Use electronic medical records 0.71
Yes 40.9
No 42.2
Computers in Exam Rooms 0.67
Yes 42.0
No 40.6
Internet Connection available for computers in Exam
Rooms
0.53
Yes 42.5
No 36.7
Use a PDA or smartphone
when seeing patients
0.001
Yes 47.1
No 36.2
CHD = coronary heart disease; PDA = personal digital assistant
*Overall P-values based on Pearson’s Chi square
†Pearson’s Chi square tests between paired groups yielded p = 0 .072
between cardiologists and family medicine physicians, p < 0 .0001 between
Table 6 Odds of using CHD risk assessment by subgroups
of physician characteristics
Characteristic Odds Ratio (95% CI)*
Specialty
Internal medicine 1.0 (referent)
Cardiology 1.95 (1.31 - 2.90)
Family medicine 1.36 (0.93 - 1.98)
Years in practice
< 10 years 1.0 (referent)
10-19 years 1.70 (1.06 - 2.73)
≥20 years 0.93 (0.61 - 1.42)
Office based care time
≥75% 1.0 (referent)
51-74% 1.61 (1.05 - 2.46)
50% 2.25 (1.33 - 3.82)
25-49% 1.21 (0.74 - 1.97)
< 25% 1.19 (0.72 - 1.57)
PDA or smartphone use 1.58 (1.17 - 2.12)
*Based on the results of a logistic regression model, adjusted for specialty,
years in practice, amount of office based care time, and use of a PDA/
smartphone.
cardiologists and general internists, and p = 0.018 between family medicine
physicians and general internists.
‡ Pearson’s Chi square tests between paired groups yielded p < 0 .003 for
respondents spending > 75% of time vs. those spending 51-74% of time, p <
0 .001 for > 75% vs. 50%, p < 0.03 for 50% of time vs. < 25%.
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individuals’ calculated 10-year CHD risk levels. For
example, use of global CHD risk is advocated by
national cholesterol treatment guidelines to better iden-
tify people who will benefit from intensive treatment
[17]. Additionally, the decision to use aspirin for pri-
mary prevention is one that needs to be weighed against
the potential for harm from gastrointestinal bleeding or
hemorrhagic stroke [18]. Due in part to the potential
harms associated with preventive pharmacotherapy, cal-
culating a patient’s global CHD risk is an important
step, allowing adjustment of the intensity of intervention
to the overall risk:benefit ratio for the patient
[3,13,17,18]. Still, in our sample, the majority of physi-
cians who were aware of CHD risk assessment tools
reported they did not use CHD risk assessment to guide
primary preventive pharmacotherapy decisions. Evidence
suggests that when 10-year coronary risk information is
given to physicians, prescription of guideline concordant
lipid-lowering and aspirin therapies is slightly improved
[19].
The most commonly endorsed barrier to CHD risk
assessment use is the perception that it is too time con-
suming. It has been shown previously that one of the
main barriers to delivery of preventive health services in
primary care is lack of time [20]. However, a recent
study found that even with limited time, primary care
physicians address many of the highest rated preventive
services, including cholesterol and BP management, ade-
quately [20]. While lack of time during primary care
patient visits is certainly a valid concern, there are many
tools available that offer quick and accurate calculation
of a patient’s CHD risk [14]. Physicians in our sample
who use a PDA or similar device when seeing patients
in the clinic were more likely to use CHD risk assess-
ments than those who do not. This suggests that CHD
risk calculator programs for PDAs or smartphones may
be a method of increasing CHD risk assessments among
physicians. Fortunately, several CHD risk calculation
tools are already available for such devices [14]. Other
CHD risk assessment tools include paper risk charts,
spreadsheet programs for computers and web-based cal-
culators [14]. Additionally, some EMR’s extract risk fac-
tor data from patients’ records and calculate and display
10-year CHD risk for clinical use. Uncertainty remains
regarding which tool for calculating CHD risk produces
the most favorable patient outcomes. One study showed
that use of a computer based clinical support system
added to a paper risk chart was not as effective as a
paper chart alone in terms of systolic BP control over
one year [21]. However, the computer based system
required manual input of patient risk factors, as opposed
to an automatic risk calculation embedded in an EMR
[21].
Other barriers are that some physicians report that
they do not find the assessment of global CHD risk use-
ful in practice and are unsure how to use the risk calcu-
lation in practice. Cardiologists were most likely to
indicate that CHD risk assessment is not useful in clini-
cal practice, which could potentially be related to the
lower proportion of patients seen for which primary
prevention (rather than secondary prevention) is of con-
cern. General internists and family physicians were
more likely to indicate that they are not familiar enough
with how to use CHD risk calculations, and that there
are no accurate or easy tools available to calculate CHD
risk. These responses suggest a need to develop educa-
tional interventions for physicians that discuss the use
of global CHD risk calculations in clinical practice
[2,3,22].
In addition to its usefulness in helping clinicians and
patients make decisions about preventive pharmacother-
apy that take into account the balance of benefits and
harms, global CHD risk could also be used to motivate
patients [15,16]. However, we found that only 40% of
Table 7 Mean ratings of importance of reasons for never or rarely calculating patients’ global CHD risk, amongst ‘non-
users’, rated 0-5* (N = 492)
All Family
Physicians
General
Internists
Cardiologists P-
value†
It is too time consuming 2.6 2.8 2.6 2.3 0.02
I do not find it useful in practice 2.2 1.9 2.0 2.9 <
0.0001
I am not familiar enough with how to use the risk calculation 2.0 2.3 2.3 1.3 <
0.0001
There are no easy to use tools available for obtaining the calculation 1.8 2.0 1.8 1.5 0.01
There are no accurate tools available for obtaining the calculation 1.3 1.3 1.4 1.2 0.51
I do not think that the calculated heart disease risk is valid for my patient
population
1.2 1.1 1.2 1.4 0.13
CHD = coronary heart disease
* “0” is the lowest importance level (not important at all), and “5” is the highest importance level (extremely important)
†Overall P-value based on analysis of variance test for significance between specialty groups
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those who use CHD risk assessments inform patients of
their global CHD risk estimate. In total, while a majority
of physicians who use CHD risk assessments use them
either to guide prescription decisions or to motivate
patients, an appreciable number do not. This suggests
that even when CHD risk is calculated by physicians in
practice, they may be unaware of how to utilize this risk
information to its full advantages.
Our findings illustrate the need for interventions to
increase uptake and effective use of global CHD risk
assessment for guiding primary prevention. Develop-
ment of effective interventions to improve guideline
adherence by physicians should consider the variety of
barriers to implementation in order to be successful
[23]. While the type of intervention that is most effec-
tive remains unknown, education in small doses as well
as passive guideline dissemination have been shown to
be ineffective methods for affecting physician behavior
change [24]. Paper and electronic reminders may be the
most effective single intervention; however, it is likely
that multiple tools will be necessary to increase guide-
line adherence among physicians [24]. The use of guide-
line concordant decision aids, programs embedded in
EMRs that automatically calculate and display risk
values and action thresholds, and risk charts in patient
exam rooms are examples of system improvements that
warrant further investigation.
Limitations
The major potential limitation of this study is that of
non-response bias. If physicians who responded to our
survey were more interested in cardiovascular disease
prevention compared to those who did not respond,
then our results may be biased. Physicians who are
more passionate about primary prevention of CVD
might be more likely to be aware of tools used to calcu-
late global CHD risk and more likely to answer ques-
tions in agreement with the utility of global CHD risk
calculation. The 92% awareness of tools to calculate glo-
bal CHD risk suggests this may be the case. Thus, our
results are likely overestimates of the awareness and
perceived usefulness of CHD risk assessments.
Additionally, significantly more family physicians
responded to our survey (41%) than did cardiologists
(30%) or general internists (29%). This could have also
contributed to overestimation of the awareness and per-
ceived usefulness of CHD risk assessments as family
physicians would be more likely than cardiologists to
focus on primary prevention of CHD in practice.
Another potential limitation is that of sampling bias. If
physicians who are members of the AAFP and ACP are
different from physicians who choose not to be mem-
bers, then our sample may not be reflective more gener-
ally of US physicians of the included specialties.
Another clue that our sample may not be representative
is the high use of EMRs by respondents. The web-based
format of our questionnaire may have also selected for
physicians who are more confident using computer
based programs (including CHD risk assessment tools)
and may potentially represent an overestimate of use of
CHD global risk assessment compared to the general
US physician population. Self-reported data is also diffi-
cult to interpret as physicians may have supplied socially
desirable responses to survey items that differ from how
they actually practice. Finally, the cross-sectional study
design identifies associations but is insufficient to deter-
mine the cause of low CHD global risk assessment use
amongst our sample.
Conclusions
Among respondents to a survey about cardiovascular
disease prevention, awareness of tools to calculate global
CHD risk is extremely high; however, the majority of
responding physicians do not use CHD risk assessments
in practice. Use of PDAs in practice is associated with
greater self-reported use of CHD risk assessment. One
perceived barrier to using global risk calculation is that
it is too time consuming. Many physicians who report
using CHD risk calculation do not use it for guiding
prescription decisions or patient motivation. Taken
together, these findings suggest that educational inter-
ventions and system improvements are needed to
improve physicians’ use of global CHD risk to support
primary preventive therapeutic decisions.
Appendix
Physician survey items
(1) Do you see patients in the office or other ambulatory
care setting?
○ Yes
○ No
(2) Please indicate your specialty:
○ Cardiology
○ Family medicine
○ General internal medicine
○ Other (please specify)
(3) Approximately what percent of your work time is
spent in office-based patient care?
○ 75% or more
○ 51-74%
○ 50%
○ 25-49%
○ Less than 25%
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(4) Which of the following best describes your office
practice setting?
○ Solo practice
○ Small group practice (2-9 clinicians)
○ Large single specialty group (10+ clinicians)
○ Large multi-specialty group (10+ clinicians)
○ Academic group practice
○ Other (please specify)
(5) Does your office practice use an electronic medical
record?
○ Yes
○ No
(6) In your office practice, do you use computers in
the exam rooms?
○ Yes
○ No
(7) Do the computers in the exam rooms have inter-
net access?
○ Yes
○ No
(8) Do you use a personal digital assistant (e.g., Palm
device, iPhone) when seeing patients in the office?
○ Yes
○ No
This section is about global coronary heart disease
(CHD) risk. An estimate of a patient’s global (or overall)
risk of having a coronary heart disease event can be
made by combining his or her risk factors in an empiri-
cally-based equation using one of a variety of tools.
(9) Have you heard about tools to calculate a patient’s
overall risk of having a coronary heart disease event in
the next 10 years (global CHD risk)?
○ Yes
○ No
(10) In terms of 10-year coronary heart disease (CHD)
risk, at what level of risk do you consider a patient to
be “high risk” for CHD events?
○ 3% or above
○ 6% or above
○ 10% or above
○ 15% or above
○ 20% or above
○ 25% or above
○ 30% or above
○ 50% or above
(11) In terms of 10-year coronary heart disease (CHD)
risk, below what level of risk do you consider a patient
to be “low risk” for CHD events?
○ 3% or less
○ 6% or less
○ 10% or less
○ 15% or less
○ 20% or less
○ 25% or less
○ 30% or less
○ 50% or less
(12) <If aware> When considering primary prevention
of coronary heart disease in adults, how often do you
obtain a calculation of a patient’s global (overall) coron-
ary heart disease risk?
○ Never
○ Rarely (one to two out of every 10 adults seen for
routine medical care)
○ Occasionally (three to five out every 10 adults seen
for routine medical care)
○ Most of the time (six to eight out of every 10
adults seen for routine medical care)
○ Always or nearly always (nine to ten out of every
10 adults seen for routine medical care)
(13) <If answered “Never” or “Rarely” above> On a scale
of 0 to 5, where 0 is not at all important and 5 is extremely
important, rate the importance of each of the following
reasons why you never or rarely obtain a calculation of a
patient’s global (overall) coronary heart disease risk.
○ I am not familiar enough with how to use the risk
calculation
○ I do not find it useful in practice
○ There are no accurate tools available for obtaining
the calculation
○ There are no easy to use tools available for obtain-
ing the calculation
○ It is too time consuming
○ I do not think that the calculated heart disease
risk is valid for my patient population
(14) <If user> Which one of the following do you
most commonly use to obtain a patient’s global (overall)
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coronary heart disease risk estimate?
○ A paper chart
○ A web-based application
○ A non-web-based computer program (e.g., spread-
sheet calculator or personal computer)
○ A program on a personal digital assistant
○ Other (please specify)
(15) <If aware> Please indicate your level of agreement
or disagreement (1 = strongly agree, 2 = agree, 3 = dis-
agree, 4 = strongly disagree) with the following state-
ments:
○ I find global CHD risk calculation useful.
○ Global CHD risk calculation improves patient
care.
○ Global CHD risk calculation leads to better deci-
sions about whether or not to recommend therapies
to prevent heart disease events.
○ Global CHD risk calculation wastes time.
○ Global CHD risk calculation increases the likeli-
hood that I will recommend risk-reducing therapies
to high-risk patients to prevent heart disease.
(16) <If user> How often do you tell the patient his/
her global (overall) coronary heart disease risk estimate?
○ Never
○ Rarely (one to two out of 10 adults for whom I
calculate risk)
○ Occasionally (three to five out of 10 adults for
whom I calculate risk)
○ Most of the time (six to eight out of 10 adults for
whom I calculate risk)
○ Always or nearly always (nine to ten out of 10
adults for whom I calculate risk)
(17) <If user> Thinking about all the patients you are
considering for primary prevention of coronary heart
disease, how often do you use a global (overall) coronary
heart disease risk estimate to guide your recommenda-
tions about lipid lowering therapy?
○ Never
○ Rarely (one to two out of 10 adults)
○ Occasionally (three to five out of 10 adults)
○ Most of the time (six to eight out of 10 adults)
○ Always or nearly always (nine to ten out of 10
adults)
(18) <If user> Thinking about all the patients you are
considering for primary prevention of coronary heart
disease, how often do you use a global (overall) coronary
heart disease risk estimate to guide your recommenda-
tions about aspirin therapy?
○ Never
○ Rarely (one to two out of 10 adults)
○ Occasionally (three to five out of 10 adults)
○ Most of the time (six to eight out of 10 adults)
○ Always or nearly always (nine to ten out of 10
adults)
(19) <If user> Thinking about all the patients you are
considering for primary prevention of coronary heart
disease, how often do you use a global (overall) coronary
heart disease risk estimate to guide your recommenda-
tions about blood pressure lowering therapy?
○ Never
○ Rarely (one to two out of 10 adults)
○ Occasionally (three to five out of 10 adults)
○ Most of the time (six to eight out of 10 adults)
○ Always or nearly always (nine to ten out of 10
adults)
(20) In what year did you graduate from medical
school? (drop-down menu)
(21) Please indicate your sex.
○ Male
○ Female
(22) In which region of the country do you practice?
○ West
○ Midwest
○ South
○ Northeast
Additional material
Additional file 1: Geographic regions of respondents vs
nonrespondents. The table shows that the geographic regions between
respondents and nonrespondents were similar.
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